BeiGene Total Long Term Liabilities 2014-2024 | ONC
BeiGene total long term liabilities from 2014 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
- BeiGene total long term liabilities for the quarter ending September 30, 2024 were $0.369B, a 22.76% decline year-over-year.
- BeiGene total long term liabilities for 2023 were $0.458B, a 13.19% decline from 2022.
- BeiGene total long term liabilities for 2022 were $0.527B, a 34.35% decline from 2021.
- BeiGene total long term liabilities for 2021 were $0.803B, a 22.41% increase from 2020.
BeiGene Annual Total Long Term Liabilities (Millions of US $) |
2023 |
$458 |
2022 |
$527 |
2021 |
$803 |
2020 |
$656 |
2019 |
$324 |
2018 |
$250 |
2017 |
$212 |
2016 |
$18 |
2015 |
$7 |
2014 |
$93 |
2013 |
$ |
BeiGene Quarterly Total Long Term Liabilities (Millions of US $) |
2024-09-30 |
$369 |
2024-06-30 |
$407 |
2024-03-31 |
$426 |
2023-12-31 |
$458 |
2023-09-30 |
$478 |
2023-06-30 |
$525 |
2023-03-31 |
$545 |
2022-12-31 |
$527 |
2022-09-30 |
$660 |
2022-06-30 |
$677 |
2022-03-31 |
$760 |
2021-12-31 |
$803 |
2021-09-30 |
$625 |
2021-06-30 |
$675 |
2021-03-31 |
$705 |
2020-12-31 |
$656 |
2020-09-30 |
$624 |
2020-06-30 |
$806 |
2020-03-31 |
$788 |
2019-12-31 |
$324 |
2019-09-30 |
$321 |
2019-06-30 |
$307 |
2019-03-31 |
$311 |
2018-12-31 |
$250 |
2018-09-30 |
$237 |
2018-06-30 |
$241 |
2018-03-31 |
$208 |
2017-12-31 |
$212 |
2017-09-30 |
$181 |
2017-06-30 |
$154 |
2017-03-31 |
$18 |
2016-12-31 |
$18 |
2016-09-30 |
$18 |
2016-06-30 |
$11 |
2016-03-31 |
$6 |
2015-12-31 |
$7 |
2015-06-30 |
|
2015-03-31 |
|
2014-12-31 |
$93 |
2013-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|